Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response

NCT02471469 · clinicaltrials.gov ↗

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG: Enzalutamide, 160mg, 40 mg soft capsules, once daily

Sponsor

Radboud University Medical Center

Collaborators

[object Object]